Carolyn Helene Baloh, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Peanut Hypersensitivity | 2 | 2022 | 163 | 0.940 |
Why?
|
Whooping Cough | 1 | 2023 | 85 | 0.870 |
Why?
|
Immune System Diseases | 1 | 2023 | 262 | 0.740 |
Why?
|
Hypersensitivity, Immediate | 1 | 2023 | 330 | 0.720 |
Why?
|
Agammaglobulinemia | 1 | 2021 | 167 | 0.710 |
Why?
|
Severe Combined Immunodeficiency | 1 | 2021 | 220 | 0.670 |
Why?
|
Common Variable Immunodeficiency | 1 | 2019 | 93 | 0.650 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2021 | 658 | 0.650 |
Why?
|
Food Hypersensitivity | 1 | 2023 | 613 | 0.540 |
Why?
|
Enzyme Replacement Therapy | 2 | 2021 | 78 | 0.380 |
Why?
|
Tetanus Toxoid | 1 | 2023 | 193 | 0.220 |
Why?
|
alpha-Glucosidases | 1 | 2020 | 45 | 0.190 |
Why?
|
Glycogen Storage Disease Type II | 1 | 2020 | 42 | 0.190 |
Why?
|
Adenosine Deaminase | 1 | 2021 | 239 | 0.170 |
Why?
|
Lymphocyte Count | 1 | 2021 | 791 | 0.170 |
Why?
|
Allergens | 2 | 2022 | 1308 | 0.160 |
Why?
|
Comorbidity | 2 | 2023 | 10362 | 0.140 |
Why?
|
Fetal Blood | 1 | 2023 | 1315 | 0.140 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2020 | 646 | 0.140 |
Why?
|
Delayed Diagnosis | 1 | 2019 | 429 | 0.130 |
Why?
|
Lymphoma, B-Cell | 1 | 2021 | 929 | 0.120 |
Why?
|
Immunoglobulin G | 2 | 2023 | 4522 | 0.120 |
Why?
|
Methotrexate | 1 | 2020 | 1711 | 0.120 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2021 | 1377 | 0.110 |
Why?
|
Infant | 4 | 2023 | 34923 | 0.110 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 2277 | 0.110 |
Why?
|
Age of Onset | 1 | 2019 | 3263 | 0.110 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1778 | 0.110 |
Why?
|
Immune Tolerance | 1 | 2020 | 2256 | 0.100 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 3614 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6516 | 0.080 |
Why?
|
Mortality | 1 | 2019 | 2851 | 0.080 |
Why?
|
B-Lymphocytes | 1 | 2021 | 4663 | 0.080 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 4143 | 0.070 |
Why?
|
Longitudinal Studies | 1 | 2023 | 13880 | 0.070 |
Why?
|
Odds Ratio | 1 | 2019 | 9846 | 0.070 |
Why?
|
Humans | 10 | 2023 | 739398 | 0.070 |
Why?
|
Infant, Newborn | 1 | 2023 | 25470 | 0.060 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 24714 | 0.050 |
Why?
|
Phenotype | 1 | 2019 | 16301 | 0.050 |
Why?
|
Pregnancy | 1 | 2022 | 29002 | 0.050 |
Why?
|
Prognosis | 1 | 2019 | 28901 | 0.040 |
Why?
|
Desensitization, Immunologic | 1 | 2022 | 483 | 0.040 |
Why?
|
Risk Factors | 1 | 2023 | 71974 | 0.030 |
Why?
|
Female | 4 | 2022 | 378853 | 0.030 |
Why?
|
World Health Organization | 1 | 2021 | 1321 | 0.030 |
Why?
|
Child | 2 | 2020 | 77033 | 0.030 |
Why?
|
Administration, Oral | 1 | 2022 | 3909 | 0.030 |
Why?
|
Young Adult | 1 | 2019 | 56255 | 0.030 |
Why?
|
Antibodies | 1 | 2020 | 2450 | 0.030 |
Why?
|
Adolescent | 1 | 2019 | 85405 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6478 | 0.020 |
Why?
|
Child, Preschool | 2 | 2022 | 40802 | 0.020 |
Why?
|
Adult | 1 | 2019 | 213394 | 0.020 |
Why?
|
Male | 2 | 2020 | 349022 | 0.020 |
Why?
|
Time Factors | 1 | 2020 | 40050 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2020 | 62693 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2020 | 76631 | 0.010 |
Why?
|